Abstract: Imidazo[1,2-a]pyridines of the formula ##STR1## wherein R.sub.a to R.sub.e are as defined herein, the enantiomers and the salts thereof, which are useful as angiotensin antagonists and for treating conditions treatable with angiotensin antagonists.

Abstract: The invention relates to new phenylethanolamines of general formula ##STR1## wherein A represents a straight-chained or branched alkylene group,B represents a bond, an alkylene group, a carbonyl or hydroxymethylene group,R.sub.1 represents a hydrogen atom, a halogen atom or a trifluoromethyl group,R.sub.2 represents a hydrogen atom or an amino group,R.sub.3 represents a cyano group, a hydrogen, chlorine or bromine atom andR.sub.4 represents a hydrogen or halogen atom, an alkyl, hydroxy, alkoxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group or an alkoxy group substituted in the end position by a carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, pyrrolidino, piperidino or hexamethyleneimino group,the optical isomers and diastereoisomers and acid addition salts thereof.

Abstract: Substituted thiazoles, oxazoles and 2-hydroxy morpholine compounds useful in the treatment of diabetes mellitus and obesity are described.

Abstract: Phenylacetic acid benzylamides having the following general structure ##STR1## wherein the substituents are defined herein, are disclosed, which compounds are hypoglcemic agents.

Abstract: A method of determining the total fibrinolytic activity in plasma, is characterized in thata) a quantity of fibrin sufficient to produce turbidity is added to a dilute platelet poor plasma sample or is produced in situ and the time dependent change in turbidity or the time-dependent formation of fibrin cleavage products is measured; orb) a chromogenic plasmin substrate and a quantity of fibrin, fibrinogen cleavage products or an enzyme which produces fibrin in situ, insufficient to produce turbidity, is added to a dilute platelet poor plasma sample and the time dependent color formation is measured.

Abstract: New diazepinones of formula I ##STR1## wherein the substituents are defined herein, which compounds exhibit favorable effects on heart rate and in view of the absence of inhibitory effects on gastric acid secretion and salivation and the absence of mydriatic effects, are suitable as vagal pacemakers for the treatment of bradycardia and bradyarrhythmia in human and veterinary medicine.

Abstract: Cyclophanes of the general formula ##STR1## wherein X.sub.1, X.sub.2, A, R and R.sub.1 to R.sub.4 are as defined herein, the enantiomers, diastereomers and addition salts thereof and, more particularly, for pharmaceutical use, the physiologically acceptable addition salts thereof, which have pharmacological properties such as lowering blood pressure, dilating the coronary blood vessels and a mild heart rate lowering activity, pharmaceutical compositions which contain these compounds and processes for preparing them.

Abstract: The invention relates to new 2-hydroxy-n-propylamines of the formulaR.sub.1 --O--CH.sub.2 --CHOH--CH.sub.2 --NH--A--R.sub.2 (I)whereinR.sub.1, R.sub.2 and A are defined as in claim 1, the tautomers, enantiomers and acid addition salts thereof, particularly for pharmaceutical use the physiologically acceptable acid addition salts thereof with inorganic or organic acids, which have valuable pharmacological properties, more particularly a simultaneous cardiotonic and .beta.-blocking activity, and the use thereof as pharmaceutical compositions and processes for preparing them.

Abstract: There is described a process for the simultaneous chemical and biological elimination of solid and liquid waste and apparatus for performing this process in the form of a loop reactor corresponding to FIG. 1 in conjunction with a specially designed nozzle which ensures an intimate mixing of substrate with air and the spraying-in of oxidizing agents while permitting only a short contact time between the oxidizing agents and the substrate.

Abstract: The present invention relates to new heteroaromatic amine derivatives of general formula ##STR1## wherein the substituents are defined hereinbelow, which have valuable pharmacological properties, particularly a heart rate lowering activity and a positive inotropic activity.

Abstract: Novel compounds of the general formula ##STR1## which have antitussive activity, wherein R.sub.1 -R.sub.4 are as defined herein.

Abstract: Disclosed are novel pyridodiazepines. These compounds, as well as certain known 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones are useful in the treatment of AIDS, ARC and related disorders associated with HIV infection.

Abstract: Disclosed are substituted bis(4-aminophenyl-sulfonees of general formula ##STR1## wherein R.sub.1 is hydrogen, alkyl or cycloalkyl; group,R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl,R.sub.3 is nitrile, C.sub.1 -C.sub.3 alkylaminocarbonyl, di C.sub.1 -C.sub.3 alkylaminocarbonyl, C.sub.3 -C.sub.7 N-cycloalkyl-C.sub.1 -C.sub.3 alkylaminocarbonyl C.sub.1 -C.sub.3 alkylamino, C.sub.1 -C.sub.3, di alkylaminocarbonyl alkoxy, alkylaminosulfonyl, di C.sub.1 -C.sub.3 alkylaminono, diC.sub.1 -C.sub.3 alkylaminosulfonyl, hydroxy C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkylcarbonyl, amino C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy C.sub.1 -C.sub.3 alkyl groupor, when R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 can be hydroxy, hydroxycarbonyl C.sub.1 -C.sub.3 alkoxy or di C.sub.1 -C.sub.3 aminocarbonylalkoxy;or, when R.sub.1 is C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 cycloalkyl and R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sub.

Abstract: The present invention relates to new 4,5,7,8-tetrahydro-6H-thiazolo[5,4-d]azepines of general formula II ##STR1## wherein the substituents are defined herein below, which compounds have valuable pharmacological properties, namely selective effects on the dopaminergic system which are achieved by stimulating (predominantly D2) dopamine receptors.

Abstract: This invention relates to pharmaceutical compositions containing quinolin-2,5-diones of formula ##STR1## wherein A, B, R.sup.1 to R.sup.3 and X are defined hereinbelow, some of which are novel, which compounds have valuable pharmacological properties, particularly analgesic antipyretic and/or antiphlogistic effects, to new intermediates and processes for preparing them.

Abstract: The specification describes a new process and apparatus for the controlled release of metered quantities of lubricating liquids or suspensions for applying a coating of lubricant to mechanically stressed zones of pressing tools in tablet-making machines, wherein the lubricating solution or suspension is fed into one or more liquid valves synchronously with the cadence of the tablet-making machine from a pressureless storage container by means of a pulsation-free pump, and any pressure variations occuring in the liquid supply line to the valves are compensated by changes in the times of opening of the valves.

Abstract: The invention relates to new morpholines and morpholine-N-oxides of formula ##STR1## wherein the substituents are defined hereunder, which compounds have valuable pharmacological properties, namely an effect on the metabolism, preferably the effect of lowering blood sugar and reducing body fat, and the effect of lowering the atherogenic .beta.-lipoproteins VLDL and LDL, and a performance enhancing effect in animals.

Abstract: 5,11-Dihydro-6H-pyrido[2,3-b][1,4]-benzo-diazepinones substituted in the 11-position corresponding to general formula I ##STR1## wherein R.sup.1 and R.sup.2 represent hydrogen atoms or alkyl groups having 1 to 3 carbon atoms, A.sup.1 is a straight-chained or branched alkylene group with 1 to 5 carbon atoms, A.sup.2 is a methylene group or, if R.sup.1 is hydrogen and R.sup.2 is methyl, A.sup.2 may also be an ethylene group, and the physiologically acceptable acid addition salts thereof are suitable for treating bradycardia and bradyarrhythmia and spasm in the colon, bladder and bronchi.

Abstract: A method for treating abstructive respiratory passage disorders which comprises the use of 5,11-dihydro-11-[[(1-methyl-4-piperidinyl)-amino]carbonyl]-6H-dibenz[b,e]a zepin-6-one; 5,11-dihydro-11-[(1-methyl-4-piperazinyl)acetyl]-6H-dibenz[b,e]azepin-6-on e, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]-6H-dibenz[b,e]azepin-6-on e, alone or in combination.

Abstract: The invention relates to new sulphonamidoethyl compounds having valuable pharmacological properties, particularly anti-thrombotic properties, and which are also thromboxane antagonists.